NovoCure (NVCR) Jefferies London Healthcare Conference 2025 summary

Mechanism of action and technology

• Tumor Treating Fields (TTFields) use electric fields to disrupt cancer cell division and induce immunogenic cell death, targeting DNA repair mechanisms and enabling combination with other therapies without added toxicity.

• The therapy is delivered via a home-use medical device, with frequency tuning and array size adapted to tumor type and location, supporting a recurring revenue model.

Commercialization and market expansion

• Built a $600M+ annual business in glioblastoma (GBM), with established reimbursement, patient support, and IP protection, achieving mid-single-digit growth and 40% market penetration in major regions.

• Expanded into non-small cell lung cancer (NSCLC) in the US, with launches in Germany, Japan, France, Spain, and plans for Italy, UK, and Canada.

• Anticipates four marketed products by end of 2026: GBM, NSCLC, pancreatic cancer, and brain metastases, leveraging shared sales forces and infrastructure.

Clinical data and pipeline

• Demonstrated survival benefits in four solid tumors: five months in GBM, three to eight months in NSCLC, two months in pancreatic cancer, and extended intracranial progression in brain metastases.

• Six-month extension in pain-free survival and reduced opioid use in pancreatic cancer, with ongoing regulatory review and medical education efforts.

• Upcoming catalysts include phase II Panova IV (metastatic pancreatic cancer, Q1 next year), Trident (earlier TTFields in GBM), and METIS (brain metastases), with additional phase III trials in first-line NSCLC and IO combinations in GBM.